Check Claims Before You Publish

 Quick Explanation Copied

 Long Explanation

Track Record and Citation Metrics

Lior Nissim (OpenAlex ID A5060326269) has 22 works, 1,024 cumulative citations, and an h-index of 11, with citation peaks from his 2014 CRISPR/RNA toolkit paper (466 citations) and 2017 synthetic immunomodulatory gene circuit paper (183 citations) in Cell. His trajectory spans early p53 biology (2003-2004, Weizmann), mammalian synthetic promoter engineering (2010-2019), and synthetic gene circuits, indicating ~20 years of sustained, focused contributions in synthetic biology, his top-scored topic (0.85) CRISPR/RNA Toolkit Paper, 466 Citations Synthetic Immunomodulatory Circuits in Cell, 183 Citations

His 2019 SPECS platform paper (Nature Communications, 92 citations) directly precedes and methodologically underpins the 2026 COMPACT work, showing a coherent, incremental research program rather than scattered output SPECS Synthetic Promoter Platform.

The COMPACT Study: Strengths and Honest Self-Correction

The 2026 COMPACT preprint reports a 5,967-promoter RNA-barcode screen yielding four validated promoters. In YTS NK cells, COMPACTs retained 58-78% of day-0 activity under starvation at day 21 versus 37-42% for native promoters, and 33-38% under hypoxia versus 15-18% COMPACT Preprint, Aug 2026.

Critically, the authors themselves report the key counterevidence: in HEK293T, CHO, and HT-1080 cells, "COMPACTs did not exhibit a consistent advantage over native promoters," and in BEAS-2B cells over 56 days, native promoter activity was comparable or higher than the best COMPACT at day 56 (though S(AHR:ARNT×5)p itself reached 114% of initial activity). This transparent self-qualification, and explicit reporting that RNA-barcode abundance failed to predict protein-level activity, reflects genuine epistemic honesty rather than positive-result spin COMPACT Cell-Type Dependence Results.

Blind Spots and Rigor Assessment

Rigor concerns: all data derive from immortalized cell lines (YTS, HEK293T, CHO, HT-1080, BEAS-2B) with n=3 biological replicates; no copy-number normalization or integration-site analysis is reported, which could confound promoter strength comparisons; no primary NK-cell or in vivo validation; only one minimal-promoter pair was tested in the bidirectional architecture; and inferential statistics (specific tests, error bars) are not captured in the evidence record. A declared conflict of interest exists: Nissim holds a patent application on these synthetic promoters, creating a commercial incentive favoring positive framing COMPACT Funding and Conflict Disclosures.

Verdict

Nissim is a competent, productive synthetic-biology toolmaker with a strong citation record in high-impact venues and a decade-long coherent promoter-engineering program. His scientific strength lies in building large-scale screening platforms and transparently reporting negative/qualifying results. His weaknesses are modest novelty (COMPACT is an evolutionary extension of SPECS), reliance on immortalized models, small replicate counts, and an unquantified patent-related incentive. An h-index of 11 at ~20 years is respectable but not elite for his field. What would change this assessment: replicated primary-cell or in vivo validation of COMPACTs, statistical details demonstrating effect robustness, and independent-lab reproduction of the YTS retention advantage.

 BGPT Author Review

Scientific Quality

Mid-career synthetic biologist with a coherent 20-year program from p53 biology to mammalian promoter engineering, an h-index of 11, and multiple high-impact first-author papers (Molecular Cell, Cell, Nature Communications). The COMPACT work shows strong engineering-scale screening ability and honest reporting of cell-type-dependent failures, but is limited to immortalized lines, small replicates, no copy-number normalization, and a patent-related conflict of interest. Solid and reliable, not yet field-defining.

Communication Quality

The COMPACT paper presents a clear problem statement (native promoter silencing/size limits), structured comparisons across five cell lines and multiple stress conditions, and explicit text acknowledging where COMPACTs underperform native promoters. Weaknesses: reported values are often ranges rather than point estimates with statistics, and the bidirectional module demonstration is thin (single minimal-promoter pair).

Author Novelty

COMPACT is an incremental evolution of his own 2019 SPECS platform (compact oligomerized-motif promoters vs cell-state-specific promoters). The bidirectional architecture and stress-robustness angle add value, but the core concept of promoter motif oligomerization and library screening is well established in the field.

Scientific Rigor

Systematic 5,967-promoter library screen with n=3 biological replicates, orthogonal validation in five cell lines, and falsifiable quantitative retention benchmarks are rigorous strengths. However: no copy-number or integration-site normalization, no captured statistical test details, RNA-barcode screening failed to predict activity (a major platform weakness), no primary-cell or in vivo data, and only one bidirectional promoter-pair configuration tested. A patent conflict of interest exists.